| LUDWIG, H., Z. ADAM, Roman HÁJEK, R. GREIL, F. KEIL, N. ZOJER, J. THALER, H. GISSLINGER and A. LANG. Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study. Blood. 2008, vol. 112, No 11, p. 1261-. |
Other formats:
BibTeX
LaTeX
RIS
@article{822045,
author = {Ludwig, H. and Adam, Z. and Hájek, Roman and Greil, R. and Keil, F. and Zojer, N. and Thaler, J. and Gisslinger, H. and Lang, A.},
article_number = {11},
journal = {Blood},
title = {Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study},
volume = {112},
year = {2008}
}
TY - JOUR
ID - 822045
AU - Ludwig, H. - Adam, Z. - Hájek, Roman - Greil, R. - Keil, F. - Zojer, N. - Thaler, J. - Gisslinger, H. - Lang, A.
PY - 2008
TI - Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
JF - Blood
VL - 112
IS - 11
SP - 1261-
EP - 1261-
ER -
LUDWIG, H., Z. ADAM, Roman HÁJEK, R. GREIL, F. KEIL, N. ZOJER, J. THALER, H. GISSLINGER and A. LANG. Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study. \textit{Blood}. 2008, vol.~112, No~11, p.~1261-.
|
